Markets:

Overview

News

Currencies

International

Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

102.25 +0.02 (+0.02%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

8 Analysts Have This to Say About Exact Sciences ↗

October 19, 2022

Analysts have provided the following ratings for Exact Sciences (NASDAQ:EXAS) within the last quarter:

Via Benzinga

Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday ↗

October 18, 2022

Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.

Via Benzinga

Expert Ratings for Exact Sciences ↗

August 03, 2022

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for Exact Sciences ↗

June 03, 2022

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022 ↗

October 19, 2022

Upgrades

Via Benzinga

Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance ↗

April 27, 2022

Via Benzinga

Amazon, Bank of America, Microsoft And Other Big Gainers From Monday ↗

October 18, 2022

U.S. stocks closed higher on Monday, with the Dow Jones gaining around 550 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

3 Growth Stocks That Could Double Your Money, According to Wall Street ↗

October 13, 2022

Investment bank analysts think these stocks will shoot through the roof once the rest of the market sees them in the same light.

Via The Motley Fool

3 Cathie Wood Stocks That Are Too Cheap to Ignore ↗

October 07, 2022

These Cathie Wood stocks are risky, but offer immense upside potential down the road, for those willing to take a more aggressive approach.

Via InvestorPlace

Is Illumina Still the Gamechanger in Genomics Sequencing?

October 04, 2022

Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused

Via MarketBeat

7 Cheap Cathie Wood Stocks to Buy in October ↗

October 03, 2022

Ark launched a new fund on Sept. 27. While you try to figure it out, here are 7 cheap Cathie Wood stocks to buy for October.

Via InvestorPlace

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗

September 27, 2022

Via Benzinga

COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗

September 23, 2022

The World Health Organization (WHO) warned that it struggles to identify and

Via Benzinga

7 Nasdaq Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later ↗

September 21, 2022

Investors should consider buying these Nasdaq stocks on the dip while they still can before the market reverses higher.

Via InvestorPlace

No More Free COVID-19 At-Home Tests, Federal Government Says ↗

August 29, 2022

CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗

August 25, 2022

Upgrades

Via Benzinga

What 9 Analyst Ratings Have To Say About Exact Sciences ↗

August 25, 2022

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:

Via Benzinga

5 Top Stocks Cathie Wood Bought This Week ↗

August 05, 2022

Cathie Wood continues to increase positions in some of her top stocks despite recession fears. She bought names like EXAS and PACB this week.

Via InvestorPlace

Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead ↗

August 05, 2022

Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.

Via Benzinga

Exact Sciences: Q2 Earnings Insights ↗

August 02, 2022

Exact Sciences (NASDAQ:EXAS) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Exact Sciences beat estimated...

Via Benzinga

Small Cap Biotech Stocks Are Trending Well ↗

July 18, 2022

Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.

Via Talk Markets

6 Cathie Wood Stocks to Buy on the Dip ↗

July 14, 2022

As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers.

Via InvestorPlace

5 Cathie Wood Stocks to Buy in June ↗

June 09, 2022

These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

Why Ark Innovation ETF Hit 52-Week Lows Today ↗

May 09, 2022

ARK Innovation ETF (ARCA:ARKK) is making new 52-week lows on Monday, led by sharp declines in the top holdings of Ark's flagship fund.

Via Benzinga

9 Health Care Stocks With Whale Alerts In Today's Session ↗

May 06, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Exact Sciences's Return On Capital Employed Insights ↗

April 28, 2022

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94...

Via Benzinga

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know ↗

April 27, 2022

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last...

Via Benzinga

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years ↗

April 27, 2022

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.